Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M6X | ISIN: US04351P1012 | Ticker-Symbol: A71
Tradegate
19.11.24
20:29 Uhr
118,00 Euro
-1,00
-0,84 %
1-Jahres-Chart
ASCENDIS PHARMA A/S ADR Chart 1 Jahr
5-Tage-Chart
ASCENDIS PHARMA A/S ADR 5-Tage-Chart
RealtimeGeldBriefZeit
118,00119,0012:54
117,00119,0008:00

Aktuelle News zur ASCENDIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaTD Cowen Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $153.002
FrAscendis Pharma rises on US launch plans of key product7
FrAscendis Pharma A/S reports results for the quarter ended September 30 - Earnings Summary5
14.11.Ascendis Pharma Reports Third Quarter 2024 Financial Results397- YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025...
► Artikel lesen
14.11.(ASND) - Analyzing Ascendis Pharma's Short Interest2
13.11.Ascendis Pharma A/S - 6-K, Report of foreign issuer-
13.11.A Glimpse of Ascendis Pharma's Earnings Potential1
06.11.Ascendis Pharma A/S (NASDAQ:ASND) Raised to Strong-Buy at Wedbush4
ASCENDIS PHARMA Aktie jetzt für 0€ handeln
04.11.Ascendis Pharma A/S's (ASND) Overweight Rating Reiterated at Cantor Fitzgerald6
04.11.Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases293- Collaboration leverages Ascendis' proprietary TransCon technologies and Novo Nordisk's expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration's...
► Artikel lesen
04.11.Ascendis Pharma A/S - 6-K, Report of foreign issuer1
09.10.Ascendis Pharma A/S - 6-K, Report of foreign issuer6
08.10.Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years3
01.10.Ascendis Pharma submits sBLA for growth hormone deficiency therapy3
30.09.Ascendis Pharma beantragt FDA-Zulassung für Wachstumshormonbehandlung bei Erwachsenen3
30.09.Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency145COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug...
► Artikel lesen
30.09.Ascendis Pharma: New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 20241
24.09.Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years1
23.09.Ascendis Pharma A/S - 6-K, Report of foreign issuer1
20.09.Ascendis Pharma prices $300M equity offering3
Seite:  Weiter >>
106 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1